REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Tendon & Joint Repair Protocol

Recovery & Healingbeginner
38
Share
Peptides

2

Avg Daily mcg

1,214

Level

beginner

Added

May 16, 2026

Overview

The Tendon and Joint Repair Protocol is a beginner-friendly recovery stack specifically formulated to address the slow-healing connective tissues that plague athletes, active individuals, and anyone dealing with chronic joint or tendon injuries. Tendons and ligaments receive limited blood supply compared to muscles, making them notoriously slow to heal. This two-peptide combination directly addresses that limitation through complementary repair mechanisms. BPC-157, administered at 250mcg twice daily, is a gastric pentadecapeptide with extensive preclinical evidence supporting its role in tendon and ligament repair. Research has demonstrated that BPC-157 accelerates the healing of severed Achilles tendons, torn MCLs, and damaged rotator cuff tissues in animal models. It works by upregulating growth hormone receptors in damaged tissue, promoting angiogenesis to increase blood supply to hypovascular tendons, and stimulating tendon fibroblast proliferation and migration. The twice-daily dosing ensures consistent peptide availability during both the inflammatory and proliferative phases of tendon healing. For localized injuries, subcutaneous injection near the affected tendon yields the best results. TB-500, dosed at 2500mcg twice weekly, complements BPC-157 by promoting cellular migration and reducing inflammation throughout the healing process. As a synthetic fragment of Thymosin Beta-4, it upregulates actin, a cell-building protein essential for tissue repair and new blood vessel formation. TB-500 has a systemic distribution pattern, meaning it reaches injured tissues throughout the body regardless of injection site. It also reduces adhesion formation between healing tissues, promoting more functional and flexible repair rather than stiff scar tissue. Together, these peptides create a powerful healing environment: BPC-157 provides targeted growth factor amplification and local vascularization, while TB-500 ensures system-wide cellular mobility and anti-inflammatory support. This combination is well-suited for tendinitis, tendinosis, ligament sprains, joint capsule injuries, and chronic overuse conditions. The protocol typically runs for 6-8 weeks, with many users reporting noticeable pain reduction and improved mobility within the first 2-3 weeks. As a beginner stack, it requires no complex cycling and carries a favorable safety profile based on available research.

Dosing Protocol

BPC-157

Twice per day

Read more about BPC-157 →

250 mcg

per dose

TB-500

Twice per week

Read more about TB-500 →

2,500 mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.